NEW WORLD MARKET STUDIES FROM MIRC

10 February 1992

Market Intelligence Research Corporation has recently published three new research reports covering worldwide markets.

The first deals with the world market for allergy products, which was valued at $5.2 billion in 1990. The report notes that up to 25% of the world's population suffers from some form of allergic disease. In particular, the incidence of allergic rhinitis and asthma have been increasing, especially in the industrialized nations.

An increasing number of sufferers are turning to over-the-counter medications rather than prescription products to deal with their allergies, which means that manufacturers are going to have to refocus their marketing efforts, according to MIRC. Moreover, opportunities for expansion are expected to be greatly impacted by the application of government cost-containment measures in all geographical markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight